Viltolarsen (Viltepso)
Duchenne Muscular Dystrophy (Exon 53)
ApprovedCommercial
Key Facts
About Nippon Shinyaku
Nippon Shinyaku's mission is to address high-unmet medical needs through pioneering science, particularly in rare diseases. Its key achievement is the development and commercialization of Viltepso (viltolarsen), an exon-skipping therapy for Duchenne muscular dystrophy, establishing its technological credibility. The company's strategy is built on deep R&D in targeted therapeutic areas, a dominant position in the Japanese market, and strategic international expansion, especially in the United States.
View full company profileTherapeutic Areas
Other Duchenne Muscular Dystrophy (Exon 53) Drugs
| Drug | Company | Phase |
|---|---|---|
| WVE-N531 | WaVe Life Sciences | Phase 1 |